Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June...
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro PR Newswire NEW YORK, July 19, 2023 NEW YORK, July 19, 2023 /PRNewswire/ -- As the...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2023...
UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads